366 related articles for article (PubMed ID: 31189583)
1. Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Pandemic and Nonpandemic Influenza Periods.
Hernández S; Muñoz-Almagro C; Ciruela P; Soldevila N; Izquierdo C; Codina MG; Díaz A; Moraga-Llop F; García-García JJ; Domínguez Á
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31189583
[TBL] [Abstract][Full Text] [Related]
2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
3. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M;
Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132
[TBL] [Abstract][Full Text] [Related]
4. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
[TBL] [Abstract][Full Text] [Related]
5. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13.
Redin A; Ciruela P; de Sevilla MF; Gomez-Bertomeu F; Gonzalez-Peris S; Benitez MA; Trujillo G; Diaz A; Jou E; Izquierdo C; Perez-Moreno MO; Moraga-Llop F; Olsina M; Vinado B; Sanfeliu E; Garcia A; Gonzalez-di Lauro S; Garcia-Garcia JJ; Dominguez A; Sa-Leao R; Muñoz-Almagro C;
Microbiol Spectr; 2021 Dec; 9(3):e0115021. PubMed ID: 34878302
[TBL] [Abstract][Full Text] [Related]
6. Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): Surveillance data from 23 sites in Catalonia, Spain.
Ludwig G; Garcia-Garcia S; Lanaspa M; Ciruela P; Esteva C; Fernandez de Sevilla M; Diaz-Conradi A; Marti C; Motje M; Galles C; Morta M; Izquierdo C; Moraga-Llop F; Campins M; Salleras L; Jane M; Dominguez A; Garcia-Garcia JJ; Muñoz-Almagro C;
PLoS One; 2020; 15(2):e0228612. PubMed ID: 32027715
[TBL] [Abstract][Full Text] [Related]
7. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study.
Guevara M; Barricarte A; Torroba L; Herranz M; Gil-Setas A; Gil F; Bernaola E; Ezpeleta C; Castilla J;
Euro Surveill; 2016; 21(14):. PubMed ID: 27103428
[TBL] [Abstract][Full Text] [Related]
8. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study.
Picazo JJ; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Amo MD; Méndez C;
Vaccine; 2019 Apr; 37(16):2200-2207. PubMed ID: 30902478
[TBL] [Abstract][Full Text] [Related]
9. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN
Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905
[TBL] [Abstract][Full Text] [Related]
10. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
11. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
Shigayeva A; Rudnick W; Green K; Chen DK; Demczuk W; Gold WL; Johnstone J; Kitai I; Krajden S; Lovinsky R; Muller M; Powis J; Rau N; Walmsley S; Tyrrell G; Bitnun A; McGeer A;
Clin Infect Dis; 2016 Jan; 62(2):139-47. PubMed ID: 26354970
[TBL] [Abstract][Full Text] [Related]
12. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
13. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
[TBL] [Abstract][Full Text] [Related]
14. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
[TBL] [Abstract][Full Text] [Related]
15. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain.
Muñoz-Almagro C; Ciruela P; Esteva C; Marco F; Navarro M; Bartolome R; Sauca G; Gallés C; Morta M; Ballester F; Raga X; Selva L;
J Infect; 2011 Aug; 63(2):151-62. PubMed ID: 21679725
[TBL] [Abstract][Full Text] [Related]
16. Trends of invasive pneumococcal disease and its serotypes in the Autonomous Community of Madrid.
Latasa Zamalloa P; Sanz Moreno JC; Ordobás Gavín M; Barranco Ordoñez MD; Insúa Marisquerena E; Gil de Miguel Á; Fernández Chávez AC; García-Comas L
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36(10):612-620. PubMed ID: 29221826
[TBL] [Abstract][Full Text] [Related]
17. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
18. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
[TBL] [Abstract][Full Text] [Related]
19. Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain.
Hernández S; Moraga-Llop F; Díaz A; de Sevilla MF; Ciruela P; Muñoz-Almagro C; Codina G; Campins M; García-García JJ; Esteva C; Izquierdo C; González-Peris S; Martínez-Osorio J; Uriona S; Salleras L; Domínguez Á
Emerg Infect Dis; 2020 Jun; 26(6):1147-1155. PubMed ID: 32441620
[TBL] [Abstract][Full Text] [Related]
20. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
